Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters Novartis holded an investor event in London to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D pipeline. Vas Narasimhan, CEO of Novartis, said “Novartis had a year of breakthrough innovation in 2019, with five potential blockbuster NME approvals. The near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth. Our operational focus is beginning to show results including accelerating timelines, reducing costs and improving productivity without compromising quality. We look forward to delivering new transformational treatment options to patients and continuing to reimagine medicine to address some of the world’s greatest unmet healthcare needs.” Key highlights to be presented at R&D Day 2019 Emerging assets that address signific...